Navigation Links
Beckman Coulter Acquires Rights to Hepatitis C Virus
Date:4/30/2008

Enables Development of Molecular Quantitative Viral Load Assay

ORANGE COUNTY, Calif., April 30 /PRNewswire-FirstCall/ -. Beckman Coulter, Inc. (NYSE: BEC) announced today that it has licensed certain rights to testing for the hepatitis C virus (HCV) from Siemens Healthcare Diagnostics. Under the agreement, Beckman Coulter can develop, manufacture and sell a quantitative viral load HCV blood test for use on the company's molecular diagnostic instrument, which is in development. As a result, Beckman Coulter expects to take a charge of $12 million in the second quarter of 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

HCV viral load testing is essential for managing patients affected by the hepatitis C virus and is used to monitor therapy for the duration of the infection. An estimated 180 million people are chronically infected with the hepatitis virus and an additional 3 to 4 million people are newly infected each year. A hepatitis C infection can cause acute hepatitis and chronic liver disease including cirrhosis and liver cancer. Two thirds of all liver transplants in developed countries are the result of these diseases(1).

Scott Garrett, chairman, president and CEO of Beckman Coulter, commented, "We are enthusiastic about the opportunity to meet our customers' growing needs for HCV testing. Our access to this intellectual property will expand the served market for our 'sample-to-result' molecular diagnostics system, expected to launch in 2010."

"We are pleased to collaborate with Beckman Coulter to broaden the availability of this important test," said Dave Okrongly, senior vice president, molecular diagnostics, Siemens Healthcare Diagnostics Division. "This agreement reaffirms Siemens' commitment to enable physicians worldwide to improve the health care they offer patients."

Garrett added, "Routine molecular testing is the fastest growing segment in clinical diagnostics and represents an important part of our growth strategy. The addition of HCV will enhance our infectious disease test menu while furthering our dedication to improving patient health and reducing the cost of care."

About Beckman Coulter

Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents approximately 78 percent of the company's 2007 annual revenue of $2.76 billion. For more information, visit http://www.beckmancoulter.com.

(1) World Health Organization (WHO) 2008. Web site accessed March 4, 2008: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html.

Contacts: Allan Harris, Investor Relations

714.773.7620

adharris@beckman.com

Mary Luthy, Corporate Communications

714.773.7964

mluthy@beckman.com


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Beckman Coulter to Present at the Bear Stearns Healthcare Conference
2. Beckman Coulter to Present at the UBS Global Life Sciences Conference
3. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
4. Beckman Coulter Declares Quarterly Dividend
5. Beckman Coulter Announces Third Quarter 2007 Results
6. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
7. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
8. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
9. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
10. Beckman Coulter to Present at the JPMorgan Healthcare Conference
11. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... , ... Information Management Services ( IMS ) is pleased to announce a ... technical foundation and is so significant it was endowed with a new name, BSI ... search results, a streamlined layout and a more intuitive format for navigating the system. ...
(Date:2/8/2016)... (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, ... present information about the company,s programs at the BIOCEO conference today ... City . --> --> ... Registered attendees can request a one on one meeting through the conference ... --> New York City . --> ...
(Date:2/8/2016)... February 8, 2016 ... or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, ... its Chlamydia trachomatis (CT) test to be launched on the ... Directive (98/79/EC), the CT test is now cleared for sale ... --> The launch of the io® CT test signals ...
(Date:2/5/2016)... Va. , Feb. 5, 2016 ATCC, ... is poised to assist the medical and life science ... around Zika Virus infection.   CDC website ... --> Zika virus is a single-stranded RNA ... includes the West Nile, Dengue and Chikungunya Viruses. Zika ...
Breaking Biology Technology:
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
(Date:1/13/2016)... , January 13, 2016 /PRNewswire/ ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the addition ... Identification Market - Estimation & Forecast ...
(Date:1/8/2016)... Connecticut , January 8, 2016 ... m-commerce market and WorldVentures ® , a privately held ... and an Inc. 5000 fastest-growing company announced ... strategic investment of $2 million in Nxt-ID to develop ... based on Nxt-ID,s Wocket ® , a unique smart ...
Breaking Biology News(10 mins):